vs
Side-by-side financial comparison of Medpace Holdings, Inc. (MEDP) and WEIBO Corp (WB). Click either name above to swap in a different company.
WEIBO Corp is the larger business by last-quarter revenue ($1.3B vs $708.5M, roughly 1.8× Medpace Holdings, Inc.). WEIBO Corp runs the higher net margin — 35.7% vs 19.1%, a 16.6% gap on every dollar of revenue. Over the past eight quarters, WEIBO Corp's revenue compounded faster (22.6% CAGR vs 17.7%).
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
Weibo Corporation is a Chinese social network company known for the microblogging website Sina Weibo. It is based in Beijing, China.
MEDP vs WB — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $708.5M | $1.3B |
| Net Profit | $135.1M | $458.3M |
| Gross Margin | — | — |
| Operating Margin | 21.6% | 29.1% |
| Net Margin | 19.1% | 35.7% |
| Revenue YoY | 32.0% | — |
| Net Profit YoY | 15.5% | — |
| EPS (diluted) | $4.65 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $708.5M | — | ||
| Q3 25 | $659.9M | $1.3B | ||
| Q2 25 | $603.3M | $841.7M | ||
| Q1 25 | $558.6M | $396.9M | ||
| Q4 24 | $536.6M | — | ||
| Q3 24 | $533.3M | $1.3B | ||
| Q2 24 | $528.1M | $833.4M | ||
| Q1 24 | $511.0M | $395.5M |
| Q4 25 | $135.1M | — | ||
| Q3 25 | $111.1M | $458.3M | ||
| Q2 25 | $90.3M | $234.8M | ||
| Q1 25 | $114.6M | $108.1M | ||
| Q4 24 | $117.0M | — | ||
| Q3 24 | $96.4M | $297.4M | ||
| Q2 24 | $88.4M | $164.6M | ||
| Q1 24 | $102.6M | $51.1M |
| Q4 25 | 21.6% | — | ||
| Q3 25 | 21.5% | 29.1% | ||
| Q2 25 | 20.9% | 30.4% | ||
| Q1 25 | 20.3% | 27.8% | ||
| Q4 24 | 23.4% | — | ||
| Q3 24 | 21.1% | 29.0% | ||
| Q2 24 | 19.9% | 28.2% | ||
| Q1 24 | 20.4% | 25.2% |
| Q4 25 | 19.1% | — | ||
| Q3 25 | 16.8% | 35.7% | ||
| Q2 25 | 15.0% | 27.9% | ||
| Q1 25 | 20.5% | 27.2% | ||
| Q4 24 | 21.8% | — | ||
| Q3 24 | 18.1% | 22.9% | ||
| Q2 24 | 16.7% | 19.8% | ||
| Q1 24 | 20.1% | 12.9% |
| Q4 25 | $4.65 | — | ||
| Q3 25 | $3.86 | — | ||
| Q2 25 | $3.10 | — | ||
| Q1 25 | $3.67 | — | ||
| Q4 24 | $3.67 | — | ||
| Q3 24 | $3.01 | — | ||
| Q2 24 | $2.75 | — | ||
| Q1 24 | $3.20 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $497.0M | $1.1B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $459.1M | $3.9B |
| Total Assets | $2.0B | $6.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $497.0M | — | ||
| Q3 25 | $285.4M | $1.1B | ||
| Q2 25 | $46.3M | $1.2B | ||
| Q1 25 | $441.4M | $1.2B | ||
| Q4 24 | $669.4M | — | ||
| Q3 24 | $656.9M | — | ||
| Q2 24 | $510.9M | $1.9B | ||
| Q1 24 | $407.0M | $2.1B |
| Q4 25 | $459.1M | — | ||
| Q3 25 | $293.6M | $3.9B | ||
| Q2 25 | $172.4M | $3.6B | ||
| Q1 25 | $593.6M | $3.5B | ||
| Q4 24 | $825.5M | — | ||
| Q3 24 | $881.4M | — | ||
| Q2 24 | $763.6M | $3.4B | ||
| Q1 24 | $671.5M | $3.3B |
| Q4 25 | $2.0B | — | ||
| Q3 25 | $1.8B | $6.9B | ||
| Q2 25 | $1.6B | $6.5B | ||
| Q1 25 | $1.9B | $6.7B | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.1B | — | ||
| Q2 24 | $1.9B | $7.1B | ||
| Q1 24 | $1.8B | $7.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $192.7M | — |
| Free Cash FlowOCF − Capex | $188.1M | — |
| FCF MarginFCF / Revenue | 26.6% | — |
| Capex IntensityCapex / Revenue | 0.6% | — |
| Cash ConversionOCF / Net Profit | 1.43× | — |
| TTM Free Cash FlowTrailing 4 quarters | $681.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $192.7M | — | ||
| Q3 25 | $246.2M | — | ||
| Q2 25 | $148.5M | — | ||
| Q1 25 | $125.8M | — | ||
| Q4 24 | $190.7M | — | ||
| Q3 24 | $149.1M | — | ||
| Q2 24 | $116.4M | — | ||
| Q1 24 | $152.7M | — |
| Q4 25 | $188.1M | — | ||
| Q3 25 | $235.5M | — | ||
| Q2 25 | $142.4M | — | ||
| Q1 25 | $115.8M | — | ||
| Q4 24 | $183.0M | — | ||
| Q3 24 | $138.5M | — | ||
| Q2 24 | $103.5M | — | ||
| Q1 24 | $147.2M | — |
| Q4 25 | 26.6% | — | ||
| Q3 25 | 35.7% | — | ||
| Q2 25 | 23.6% | — | ||
| Q1 25 | 20.7% | — | ||
| Q4 24 | 34.1% | — | ||
| Q3 24 | 26.0% | — | ||
| Q2 24 | 19.6% | — | ||
| Q1 24 | 28.8% | — |
| Q4 25 | 0.6% | — | ||
| Q3 25 | 1.6% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 1.8% | — | ||
| Q4 24 | 1.4% | — | ||
| Q3 24 | 2.0% | — | ||
| Q2 24 | 2.4% | — | ||
| Q1 24 | 1.1% | — |
| Q4 25 | 1.43× | — | ||
| Q3 25 | 2.22× | — | ||
| Q2 25 | 1.65× | — | ||
| Q1 25 | 1.10× | — | ||
| Q4 24 | 1.63× | — | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 1.32× | — | ||
| Q1 24 | 1.49× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
WB
| Income from operations | $373.2M | 29% |
| Shares used in computing diluted net income per share attributable to Weibos shareholders | $268.1M | 21% |
| Shares used in computing basic net income per share attributable to Weibos shareholders | $238.6M | 19% |
| Value-added services | $186.1M | 14% |
| Less: Income tax expenses | $113.2M | 9% |
| Investment related income, net | $45.0M | 4% |
| Product development | $16.7M | 1% |
| General and administrative | $10.6M | 1% |
| Sales and marketing | $7.1M | 1% |
| Accretion to redeemable non-controlling interests | $3.0M | 0% |
